The Commercial Shift Reshaping Women's Health Innovation

The market isn't just getting bigger. It's getting more complex.

Women’s health companies are expanding beyond single products, single buyers, and single channels. Consumer models are intersecting with employers, providers, payers, health systems, and strategic partners—creating new opportunities for growth and new demands on commercialization. This article explores the commercial shift reshaping women’s health and what it means for companies building the next generation of scalable healthcare businesses.

By Julie Spence, Founder + Principal

The Market Is Changing

For much of the recent growth in women’s health, consumers helped prove the market. Women searched for better options, paid out of pocket, joined waitlists, sought virtual care, and demonstrated demand in categories that had historically been overlooked or underserved.

But the market is evolving.

Companies that began by reaching women directly are increasingly expanding into employers, providers, payers, health systems, and strategic partnerships. With each new opportunity comes a different buyer, value proposition, evidence requirement, and path to adoption.

The market isn't just getting bigger. It's getting more complex.

That complexity creates opportunity—but it also changes what companies need to build to capture it.

One Innovation. Multiple Buyers.

One of the defining commercialization challenges in women’s health is that the person experiencing the problem may not be the person making the purchasing decision.

A patient may use the solution. A clinician may recommend it. An employer may sponsor it. A health plan may reimburse it. A health system may integrate it. Each enters the decision with different priorities and a different definition of value.

Every new buyer introduces a new value equation.

The innovation hasn't changed. But the commercial argument has.

Understanding who uses the product, who influences adoption, who controls the budget, and what each needs to believe becomes essential to building a repeatable path to market.

From Consumer Demand to Enterprise Adoption

Consumer models have played an important role in women’s health—creating awareness, validating unmet need, and giving women direct access to solutions the traditional healthcare system often failed to provide.

But consumer traction doesn't automatically translate into enterprise adoption.

A DTC value proposition doesn't automatically become an enterprise value proposition.

An employer needs a business case. A payer may require evidence of clinical and economic value. A provider may care about outcomes and workflow. A health system may evaluate integration, capacity, reimbursement, and operational impact.

Moving from DTC to B2B—or increasingly B2B2C—isn't simply adding another sales channel. It changes the buyer, the value proposition, the evidence required, and the path to adoption.

More Opportunity Requires More Choices

As the market expands, so do the potential paths to growth. Consumers, employers, payers, providers, health systems, partnerships, new populations, and new markets may all represent legitimate opportunities.

But opportunity and priority aren't the same thing.

More market opportunity creates more commercial choices. It also raises the cost of making the wrong ones.

Companies have finite capital, time, and commercial capacity. The question shifts from Where could we grow? to Where should we grow first?

Commercial scale requires making deliberate choices about which markets, buyers, and channels create the strongest path to growth—and in what order.

Evidence Has to Travel With the Business Model

As companies move across buyers and channels, the evidence required to support adoption changes too.

Clinical outcomes may matter to a provider. A payer may need clinical and economic value. An employer may look for utilization, outcomes, and ROI. A health system may need evidence of workflow and operational impact.

The evidence that proves an innovation works may not be the evidence that gets it bought.

Commercialization requires understanding what each buyer needs to believe—and building the proof that helps them make the decision.

As the business model evolves, the evidence strategy has to evolve with it.

Commercial Infrastructure Has to Catch Up

As markets, buyers, and channels multiply, the capabilities required to support them have to evolve too.

Market intelligence sharpens where to compete. Product marketing translates value across buyers. Evidence supports adoption. Pricing captures value. Sales enablement turns strategy into buyer conversations. Go-to-market connects those capabilities around a repeatable path to growth.

Commercial complexity can increase faster than commercial capability.

The answer isn't simply more sales or more marketing. It's building the commercial infrastructure required for the business the company is becoming.

The Next Generation of Women’s Health Companies

The growth of women’s health isn't simply creating more companies. It's creating more sophisticated healthcare businesses.

Companies that began with a single product may expand across a broader care journey. Consumer brands may develop enterprise businesses. Digital health companies may intersect with clinical care. Diagnostics may require provider adoption and payer coverage. Partnerships may become important distribution channels.

The next generation of women’s health companies won't simply need to reach more customers. They'll need to navigate more complex markets.

That will require commercial capabilities that evolve alongside the innovation—and organizations built to make increasingly complex market decisions with clarity and discipline.

The Commercial Shift

The commercial shift reshaping women’s health isn't simply a move from DTC to B2B. It's a move toward more complex markets, buyers, channels, evidence requirements, and paths to adoption.

The opportunity in women’s health is expanding. The companies that scale will be the ones that build the commercial capabilities to expand with it.

That complexity creates enormous opportunity—but capturing it will require more than great innovation. Companies will need to make sharper choices about where to compete, understand what creates value for different buyers, build the evidence that supports adoption, and develop commercial models that can scale.

The opportunity in women’s health is expanding.

The companies that scale will be the ones that build the commercial capabilities to expand with it.